Hanmi Pharm Valuation Multiples

Hanmi Pharm Overview

About Hanmi Pharm

Hanmi Pharm Co Ltd is a Korea-based company, engaged in manufacturing and marketing of medicines, medical supplies and raw materials for medicines. The company makes strenuous and enthusiastic efforts to develop treatments for diabetes, obesity, cancer, autoimmune and rare disease to keep everyone's health and improve their quality of life. The group distributes its products within Korean market and to overseas markets.

Founded

1973

HQ

Employees

N/A

Website

hanmi.co.kr

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $1B

EBITDA: $243M

EV

$4B

Valuation Multiples

Multiples.vc

Start free trial

Hanmi Pharm Financials

Hanmi Pharm reported last 12-month revenue of $1B and EBITDA of $243M.

In the same LTM period, Hanmi Pharm generated $614M in gross profit, $243M in EBITDA, and $129M in net income.

Hanmi Pharm P&L

In the most recent fiscal year, Hanmi Pharm reported revenue of $1B and EBITDA of $239M.

Hanmi Pharm expects next 12-month revenue of XXX and NTM EBITDA of XXX

Hanmi Pharm Stock Performance

Hanmi Pharm has current market cap of $4B, and enterprise value of $4B.

Hanmi Pharm's stock price is $329.59.

Hanmi Pharm Valuation Multiples

Hanmi Pharm trades at 4.0x EV/Revenue multiple, and 17.8x EV/EBITDA.

Hanmi Pharm Financial Valuation Multiples

As of April 10, 2026, Hanmi Pharm has market cap of $4B and EV of $4B.

Equity research analysts estimate Hanmi Pharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Hanmi Pharm has a P/E ratio of 32.4x.

Hanmi Pharm Margins & Growth Rates

Hanmi Pharm's revenue in the last 12 month grew by 8%.

Hanmi Pharm's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Hanmi Pharm's rule of X is 43% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Hanmi Pharm Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Hanmi Pharm M&A Activity

Hanmi Pharm acquired XXX companies to date.

Last acquisition by Hanmi Pharm was on XXXXXXXX, XXXXX. Hanmi Pharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Hanmi Pharm Investment Activity

Hanmi Pharm invested in XXX companies to date.

Hanmi Pharm made its latest investment on XXXXXXXX, XXXXX. Hanmi Pharm invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).